Trial Profile
Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+Hib) Vaccine in Healthy Korean Infants.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Hib-DTaP-poliovirus vaccine (Primary) ; DTaP poliovirus vaccine; Hib vaccine conjugate; Pneumococcal 11-valent vaccine conjugate; RIX 4414
- Indications Diphtheria; Haemophilus infections; Pertussis; Pneumococcal infections; Poliomyelitis; Rotavirus infections; Tetanus
- Focus Pharmacodynamics; Registrational
- 27 Jul 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.